A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
636actual
Sites
1
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-07-09 | actual | When the study began enrolling |
| Primary completion | 2025-11-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-30 | actual | The whole study's end, after follow-up |
| First posted | 2022-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Valvular Atrial Fibrillation (NVAF)
Primary outcomes
what the primary-completion date above is the date OFAnticoagulant (OA) cohort: Distribution of participants starting any type of anticoagulant direct-acting oral anticoagulant (DOAC) or Vitamin K antagonist (VKA) treatment
measured At Enrollment, up to 12 months
Non-Anticoagulant (Not-OA) cohort: Distribution of participants not starting any type of anticoagulant (DOAC) or (VKA) treatment
measured At Enrollment, up to 12 months
Treatment switch: Change of antithrombotic drug (in terms of active principle) during the 12-month observational period
measured Up to approximately 12 months
Distribution of participants with persistence to the first treatment strategy: No switches nor interruptions of greater than 60 days in the first administered antithrombotic strategy (including no treatments) during the 12-month observational period
measured Up to approximately 12 months
Distribution of participants with net clinical outcomes defined as occurrence of stroke, systemic embolism, major bleeding or death
measured Up to approximately 12 months
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed